The relationship between the daily dose, the plasma concentration of AD-5423 (blonanserin), and its plasma anti-dopamine (D2) and anti-serotonin (5-HT2A) activity, and the plasma serotonin/dopamine (S/D) ratio

被引：1
|
作者：
Suzuki, H [1 ]
Morokawa, Y [1 ]
Gen, K [1 ]
Takagi, H [1 ]
Yamaguchi, N [1 ]
Tanaka, C [1 ]
Aoba, A [1 ]
机构：
[1] St Marianna Univ, Sch Med, Dept Neuropsychiat, Kawasaki, Kanagawa, Japan
来源：
INTERNATIONAL CLINICAL PSYCHOPHARMACOLOGY | 2003年 / 18卷 / 03期
关键词：
D O I：
10.1097/00004850-200305000-00039
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
引用
收藏
页码：187 / 187
页数：1
相关论文
共 50 条
  • [1] The relationship between the daily dose, the plasma concentration of blonanserin, and its plasma anti-dopamine D2 and anti-serotonin 5-HT2A activity
    Suzuki, Hidenobu
    Gen, Keishi
    HUMAN PSYCHOPHARMACOLOGY-CLINICAL AND EXPERIMENTAL, 2010, 25 (04) : 342 - 346
  • [2] The relationship between the plasma concentration of blonanserin, and its plasma anti-serotonin 5-HT2A activity/anti-dopamine D2 activity ratio and drug-induced extrapyramidal symptoms
    Suzuki, Hidenobu
    Gen, Keishi
    PSYCHIATRY AND CLINICAL NEUROSCIENCES, 2012, 66 (02) : 146 - 152
  • [3] Relationship between daily dose of atypical antipsychotic and ratio of serotonin (5-HT2A) activity to anti-dopamine (D2) activity (S/D ratio) in plasma comparison between risperidone and zotepine
    Akimoto, T
    Morokawa, Y
    Suzuki, H
    Gen, K
    Yamaguchi, N
    Aoba, A
    INTERNATIONAL CLINICAL PSYCHOPHARMACOLOGY, 2003, 18 (03) : 183 - 183
  • [4] Comparison of the anti-dopamine (D2) and anti-serotonin (5-HT2A) activities of chlorpromazine and novel antipsychotics parent compounds and metabolites thereof
    Inoue, Y
    Morokawa, Y
    Onohara, A
    Sekiguchi, G
    Akimoto, T
    Suzuki, H
    Gen, K
    Yanagida, H
    Kamimura, M
    Yamaguchi, N
    Tanaka, A
    Aoba, A
    INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY, 2004, 7 : S422 - S422
  • [5] Comparison of the anti-dopamine D2 and anti-serotonin 5-HT2A activities of chlorpromazine, bromperidol, haloperidol and second-generation antipsychotics parent compounds and metabolites thereof
    Suzuki, Hidenobu
    Gen, Keishi
    Inoue, Yuichi
    JOURNAL OF PSYCHOPHARMACOLOGY, 2013, 27 (04) : 396 - 400
  • [6] Functional crosstalk and heteromerization of serotonin 5-HT2A and dopamine D2 receptors
    Albizu, Laura
    Holloway, Terrell
    Gonzalez-Maeso, Javier
    Sealfon, Stuart C.
    NEUROPHARMACOLOGY, 2011, 61 (04) : 770 - 777
  • [7] Hetero-dimerization of serotonin 5-HT2A and dopamine D2 receptors
    Lukasiewicz, Sylwia
    Polit, Agnieszka
    Kendracka-Krok, Sylwia
    Wedzony, Krzysztof
    Mackowiak, Marzena
    Dziedzicka-Wasylewska, Marta
    BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR CELL RESEARCH, 2010, 1803 (12): : 1347 - 1358
  • [8] A NOVEL CELL LINE FOR STUDYING DOPAMINE D2 AND SEROTONIN 5-HT2A HETERODIMERIZATION
    Gomez Fernandez, S.
    Lopez-Gimenez, J. F.
    Varela, M. J.
    Marcia-Rivas, M. D.
    Cadavid, M., I
    Brea, J.
    Loza, M., I
    BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY, 2015, 117 : 38 - 38
  • [9] Anatomical relationships between serotonin 5-HT2A and dopamine D2 receptors in living human brain
    Ishii, Tatsuya
    Kimura, Yasuyuki
    Ichise, Masanori
    Takahata, Keisuke
    Kitamura, Soichiro
    Moriguchi, Sho
    Kubota, Manabu
    Zhang, Ming-Rong
    Yamada, Makiko
    Higuchi, Makoto
    Okubo, Yoshinori
    Suhara, Tetsuya
    PLOS ONE, 2017, 12 (12):
  • [10] Correlations among extra pyramidal symptoms, the perospirone daily dose, the plasma concentrations of perospircine and ID15036, the plasma anti-D2 and anti-5-HT2A activity and anti-5-HT2A/D2 ratio
    Miyake, N
    Morokawa, Y
    Sekiguchi, G
    Akimoto, T
    Suzuki, H
    Gen, K
    Kamimura, M
    Takagi, H
    Tanaka, A
    Aoba, A
    INTERNATIONAL CLINICAL PSYCHOPHARMACOLOGY, 2005, 20 (03) : A1 - A1
12345